Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

PURPOSE: To identify prognostic factors associated with survival beyond 4 years and overall response in patients with metastatic melanoma treated with high-dose bolus i.v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines. STUDY DESIGN: 684 consecutive pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smith, Franz O., Downey, Stephanie G., Klapper, Jacob A., Yang, James C., Sherry, Richard M., Royal, Richard E., Kammula, Udai S., Hughes, Marybeth S., Restifo, Nicholas P., Levy, Catherine L., White, Donald E., Steinberg, Seth M., Rosenberg, Steven A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2656367/
https://ncbi.nlm.nih.gov/pubmed/18765555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0116
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados